Metastatic hormone-naïve prostate cancer: a distinct biological entity

Corres-Mendizabal, Jon; Martín-Martín, Natalia; Carracedo, Arkaitz; Zacchi, Francesca; Mateo, Joaquin

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Corres-Mendizabal, Jon
dc.contributor.author	Martín-Martín, Natalia
dc.contributor.author	Carracedo, Arkaitz
dc.contributor.author	Zacchi, Francesca
dc.contributor.author	Mateo, Joaquin
dc.date.accessioned	2024-09-25T10:02:54Z
dc.date.available	2024-09-25T10:02:54Z
dc.date.issued	2024-09
dc.identifier.citation	Corres-Mendizabal J, Zacchi F, Martín-Martín N, Mateo J, Carracedo A. Metastatic hormone-naïve prostate cancer: a distinct biological entity. Trends in Cancer. 2024 Sep;10(9):825–41.
dc.identifier.issn	2405-8025
dc.identifier.uri	https://hdl.handle.net/11351/11963
dc.description	Experimental models; Metastasis; Prostate cancer
dc.description.abstract	Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.
dc.language.iso	eng
dc.publisher	Elsevier
dc.relation.ispartofseries	Trends in Cancer;10(9)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Pròstata - Càncer - Tractament
dc.subject	Pròstata - Càncer - Prognosi
dc.subject	Metàstasi
dc.subject.mesh	Prostatic Neoplasms
dc.subject.mesh	/therapy
dc.subject.mesh	Neoplasm Metastasis
dc.subject.mesh	Prognosis
dc.title	Metastatic hormone-naïve prostate cancer: a distinct biological entity
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1016/j.trecan.2024.06.005
dc.subject.decs	neoplasias de la próstata
dc.subject.decs	/terapia
dc.subject.decs	metástasis neoplásica
dc.subject.decs	pronóstico
dc.relation.publishversion	https://doi.org/10.1016/j.trecan.2024.06.005
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Corres-Mendizabal J] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. [Zacchi F] Section of Innovation BiomedicineOncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martín-Martín N] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Translational Prostate Cancer Research Laboratory, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Carracedo A] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Translational Prostate Cancer Research Laboratory, CIC bioGUNE-Basurto, Biobizkaia Health Research Institute, Barakaldo, Bizkaia, Spain. Ikerbasque, Basque Foundation for Science, Bilbao, Spain. Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bilbao, Spain
dc.identifier.pmid	39048488
dc.rights.accessrights	info:eu-repo/semantics/openAccess